Figure 1.

(A) Isolated mesenteric microvessels obtained from untreated C57BL/6 mice were pre-contracted with 3 μmol/L noradrenaline (NA) and submitted to cumulative concentrations of the endothelium-dependent vasodilator acetylcholine (ACh, 10 nmol/L to 10 μmol/L) in the absence of any previous treatment (Control) or after receiving 50 ng/mL visfatin/eNampt, 10 µmolL FK 866, or both visfatin/eNampt plus FK 866. (B) Isolated mesenteric microvessels were obtained from C57BL/6 mice infused during 7 days with saline solution, visfatin/eNampt (100 ng/kg/day), FK 866 (2.4 mg/kg/day) or both visfatin/eNampt plus FK 866, through the subcutaneous implantation of osmotic mini-pumps. The isolated vessels were also pre-contracted with NA and submitted to cumulative concentrations of ACh. (C) Isolated mesenteric microvessels obtained from untreated C57BL/6 mice submitted to NA and ACh in Control conditions or after receiving 50 ng/mL visfatin/eNampt, 1 µmol/L CLI 095, or both visfatin/eNampt plus CLI 095. (D) Isolated mesenteric microvessels from C57BL/6 mice infused with saline solution or visfatin/eNampt (100 ng/kg/day) for 7 days, and receiving also the i.p. administration of CLI 095 (3 mg/kg/day) or analogous amounts of saline during the 7 days. (E) Isolated mesenteric microvessels obtained from untreated C57BL/6 mice pre-contracted with NA and submitted to ACh in Control conditions or after receiving 10 µmol/L nicotinamide mononucleotide (NMN), 1 µmolL CLI 095, or both NMN plus CLI 095. The curves (mean ± SEM) are expressed as the percentage of the previous NA-evoked contraction, which is indicated in the Tables S1 and S2, as well as the respective pEC₅₀ values. For every curve, 4 to 15 segments were used, obtained from 3 to 8 different animals. *p < 0.05 vs respective control or saline. #p < 0.05 vs respective visfatin/eNampt or NMN.